Physician

Michelle Theresa Ashworth, M.D.

According to 2025 Medicare claims, Michelle Ashworth, M.D. (NPI: 1477874477) practices hematology/oncology in the Austin-Round Rock-San Marcos, TX market, with the plurality of this provider's patient population coming from Williamson, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78681-4019.

Ashworth's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 693 traditional Medicare patients, billed 201,974 HCPCS/CPT codes, and received $3,033,658 in Medicare payments. The top billing code was 96365 (Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less). Part D data shows 1,572 prescription claims across 253 beneficiaries totaling $2,935,080 in drug costs, led by Ojjaara (Momelotinib Dihydrochloride). DME data shows 29 claims. Open Payments data shows 2 records totaling $35. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $393,069 to $3,033,658. Similarly, Part D prescription costs have moved sharply higher in recent years, from $22,948 to $2,935,080. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	178	15,665	$393,069
2016	471	86,990	$864,268
2017	530	117,766	$1,188,426
2018	595	166,379	$1,980,640
2019	678	215,813	$2,545,919
2020	755	243,102	$3,002,628
2021	844	207,729	$3,157,761
2022	850	225,816	$2,769,162
2023	719	192,966	$2,843,292
2024	693	201,974	$3,033,658

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	56	299	$22,948
2016	113	772	$331,410
2017	129	910	$489,985
2018	144	1,047	$501,412
2019	200	1,367	$756,004
2020	202	1,585	$1,025,390
2021	237	1,355	$1,675,479
2022	245	1,561	$2,742,557
2023	240	1,575	$2,378,962
2024	253	1,572	$2,935,080

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$20,648
2016	N/R	24	$561
2017	N/R	N/R	N/R
2018	N/R	15	$4,194
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	34	$1,578
2023	N/R	31	$10,608
2024	N/R	29	$817

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	175	337	$45
96375	Injection of additional new drug or substance into vein	155	497	$11
80053	Blood test, comprehensive group of blood chemicals	158	602	$10
36415	Insertion of needle into vein for collection of blood sample	248	841	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	236	846	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ojjaara	Momelotinib Dihydrochloride	15	480	$385,383
Ninlaro	Ixazomib Citrate	26	728	$333,829
Calquence	Acalabrutinib Maleate	19	570	$281,608
Revlimid	Lenalidomide	13	343	$258,664
Imbruvica	Ibrutinib	13	364	$212,574

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$573
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$35	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michelle Theresa Ashworth, M.D.?

Tedicare shows public-source Medicare data for Michelle Theresa Ashworth, M.D. (NPI 1477874477), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michelle Theresa Ashworth, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michelle Theresa Ashworth, M.D.?

Michelle Theresa Ashworth, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Michelle Theresa Ashworth, M.D. have Open Payments data?

Michelle Theresa Ashworth, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.